Abstract BACKGROUND Cardiovascular diseases, largely driven by hypertension, remain the leading cause of mortality worldwide. Angiotensin‐I‐converting enzyme (ACE) inhibition is a well‐established therapeutic approach; however, synthetic inhibitors are frequently associated with adverse effects.
Fátima Rubio‐Senent +5 more
wiley +1 more source
Pharmacological Treatment of Interstitial Lung Diseases: A Novel Landscape for Inhaled Agents
Interstitial lung diseases (ILDs) encompass a heterogeneous group of over 200 disorders that require individualized treatment. Antifibrotic agents, such as nintedanib and pirfenidone, have remarkably revolutionized the treatment landscape of patients ...
Vito D’Agnano +8 more
doaj +1 more source
Background Pulmonary arterial hypertension is a hemodynamic disorder. Signs and symptoms are generally difficult to recognize because they are non-specific. The current treatment for pulmonary arterial hypertension offers no cure or prevention; therefore,
Alan David Kaye +4 more
doaj +1 more source
Angiotensin-converting enzyme inhibitors and cytokines in heart failure: dose and effect?∗∗Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology. [PDF]
Tyrosine hydroxylase (TH), a rate-limiting step in catecholamine synthesis in which its activity influences Alzheimer disease, Parkinson disease, and IQ of schizophrenia patients, has been studied for a long time.
Ai, J. +5 more
core +1 more source
Role of cyclooxygenase in the vascular response to locally delivered acetylcholine in Caucasian and African descent individuals [PDF]
This is an accepted manuscript of an article published by Elsevier in Microvascular Research on 17/01/2017, available online: https://doi.org/10.1016/j.mvr.2017.01.005 The accepted version of the publication may differ from the final published version.©
Eglin, CM +3 more
core +3 more sources
Inhibiting the SUMOylation modification of TRPM4 can prevent the vascular endothelial damage caused by ATO. Inhibition of TRPM4 SUMOylation, either pharmacologically by GA or genetically by the K618R mutation, protects against ATO‐induced vascular endothelial damage.
Ting‐Ting Tong +18 more
wiley +1 more source
Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats [PDF]
This protocol describes the use of in vitro television microscopy to evaluate vascular function in isolated cerebral resistance arteries (and other vessels), and describes techniques for evaluating tissue perfusion using Laser Doppler Flowmetry (LDF) and
Allen, L. Adrienne +6 more
core +1 more source
Is there NO treatment for severe sepsis? [PDF]
Sepsis is a systemic inflammatory response syndrome in the presence of suspected or proven infection, and it may progress to or encompass organ failure (severe sepsis) and hypotension (septic shock).
Bredan, Amin, Cauwels, Anje
core +2 more sources
ABSTRACT Background Schizophrenia is characterized by positive, negative, and cognitive symptoms. Current pharmacological treatments often fail to address cognitive deficits. In this review of clinical trials, we aim to identify studies that explore neurobiological (non‐psychological) strategies to address Cognitive Impairment Associated with ...
Bahareh Peyrovian +3 more
wiley +1 more source
Stable coronary syndromes: pathophysiology, diagnostic advances and therapeutic need [PDF]
The diagnostic management of patients with angina pectoris typically centres on the detection of obstructive epicardial CAD, which aligns with evidence-based treatment options that include medical therapy and myocardial revascularisation.
Berry, Colin +2 more
core +1 more source

